RESUMEN
Aim To research the neuroprotective effect of Haikun Shenxi (HKSX) medicated serum on N2a/ App695 cells and the underlying mechanism. Methods HKSX medicated serum was prepared and carbohydrate components in it was analyzed using high performance thin layer chromatography (HPTLC) . N2a/ App695 cells were intervened with HKSX medicated serum, the cytotoxicity of HKSX medicated serum was measured by MTT; AP[_
RESUMEN
Objective:To observe the clinical efficacy of sacubitril-valsartan combined with Haikun Shenxi in the treatment of chronic left heart failure with renal insufficiency.Methods:A total of 80 patients with chronic left heart failure and renal insufficiency who were admitted to Dalian Municipal Central Hospital from October 2019 to October 2020 were selected as the research objects. They were divided into two groups by random digits table method, 40 cases in each group. The control group was treated with sacubitril-valsartan. The observation group was based on the control group plus Haikun Shenxi Capsule, and N-terminal pro-brain natriuretic peptide (NT-proBNP), heart function indexes, kidney function indexes, blood gas indexes and quality of life in two groups were compared.Results:NT-proBNP, serum creatinine and blood urea nitrogen in the observation group were significantly lower than those in the control group after treatment: (1 034.27 ± 87.33) μg/L vs. (1 421.46 ± 105.54) μg/L, (240.53 ± 45.26) μmol/L vs. (284.52 ± 52.47) μmol/L, (12.05 ± 1.87) mmol/L vs. (15.79 ± 1.87) mmol/L, the difference was statistically significant ( t = 17.88, 4.01 and 8.62; P<0.01); left ventricular end-diastolic dimension (LVEDD) after treatment in the observation group was significantly lower than that in the control group: (46.12 ± 1.05) mm vs. (48.81 ± 1.74) mm, left ventricular ejection fraction (LVEF) and cardiac index (CI) were significantly higher than those in the control group: (49.95 ± 2.17)% vs. (45.24 ± 3.22)%, (2.98 ± 0.55) L/(min·m 2) vs. (2.45 ± 0.73) L/(min·m 2), the difference was statistically significant ( t = 7.67, 8.38 and 3.66; P<0.01); the blood gas index arterial partial pressure of carbon dioxide (PaCO 2) in the observation group after treatment was significantly lower than that in the control group: (46.34 ± 3.52) mmHg (1 mmHg = 0.133 kPa) vs. (51.63 ± 4.25) mmHg, arterial partial pressure of oxygen (PaO 2), oxygen saturation of haemoglobin (SO 2), pH, HCO 3-, base excess (BE) were significantly higher than the control group: (69.35 ± 5.12) mmHg vs. (62.45 ± 4.86) mmHg, (90.46 ± 4.02)% vs. (85.36 ± 4.32)%, 7.32 ± 0.12 vs. 7.22 ± 0.15, (23.1 ± 2.0) mmol/L vs. (21.5 ± 1.9) mmol/L, (-1.57 ± 0.67) mmol/L vs. (-2.15 ± 0.85) mmol/ L, the differences were statistically significant ( t = 6.06, 6.18, 5.47, 3.33, 3.67 and 3.39; P<0.01); the quality of life scores PD, ED, OD and TS in the observation group after treatment were lower than those in the control group: (17.80 ± 3.11) scores vs. (22.35 ± 2.72) scores, (12.28 ± 2.10) scores vs. (15.74 ± 1.73) scores, (18.27 ± 1.69) scores vs. (25.54 ± 2.33) scores, (46.68 ± 3.15) scores vs. (62.17 ± 3.63) scores, the differences was statistically significant ( t = 6.97, 8.05, 15.30 and 20.38; P<0.01). Conclusions:The sacubitril-valsartan combined with Haikun Shenxi in the treatment of chronic left heart failure with renal insufficiency has a significant clinical effect. It could effectively improve the patient's heart and kidney function and blood gas indicators, and further improve the patient's quality of life.
RESUMEN
Aim To study the modulation effects of HKSX capsule on Alzheimer's disease (AD) and to preliminarily explore its mechanism using SAMP8 as an AD model.Methods SAMP8 mice aged 4 months were randomly divided into model group ( P8 group) , HKSX low-dose group (L-HKSX group) , HKSX high- dose group ( H-HKSX group) , and senescence-accel- erated mouse/resistance 1 (SAMR1 ) at the same age was used as normal control group ( R1 group).New object recognition and Morris water maze experiments were used to detect the learning and memory abilities of each group.Levels of A(3, _40 and A(3, 42 were detected by ELISA, and the expression levels of LC3- U , p62, Beclin-1 , PSD95 and Syn in hippocampus of each group were detected by Western blot.Results Compared with model group, both low and high doses of HKSX could enhance the D1 in new object recognition test, increase number of crossing the platform anrl the time spent in the target quadrant, and shorten the escape latency.Besides, it also enhanced the clearance °f Ap, _40 and AfJ, _42 , up-regulated the relative expression of Beclin-1 and LC3- II and down-regulated the expression of P62.In addition, it increased the expression of synaptic-related proteins PSD95 and Syn.Conclusions HKSX capsule can regulate the expression of autophagy-related proteins and improve autoph- agv dysfunction, which in turn reduce the deposition of A(3 in vivo to alleviate its cytotoxicity and improve synaptic plasticity.Thus, HKSX can improve the learning and memory deficits of AD mice.
RESUMEN
OBJECTIVE:To systematically review therapeutic efficacy of Haikun shenxi capsule in the treatment of chronic renal failure (CRF).METHODS:Retrieved from Central,PubMed,EMBase,CJFD,CBM,VIP and Wanfang database,randomized clinical trials (RCTs) about Haikun shenxi capsule combined with routine treatment (trial group)vs.single routine treatment (control group) in the treatment of CRF were collected.Meta-analysis was performed by Rev Man 5.3 software after screening literature,extracting data and evaluating quality by using risk bias evaluation of Cochrane collaboration network.RESULTS:A total of 10 RCTs were included eventually,involving 704 patients.The results of analysis showed that compared to general therapy,Haikun shenxi capsule could improve total effective rate [RR =4.42,95 ％ CI (2.70,7.22),P＜ 0.001],and could reduce SCr[MD =-140.37,95 ％ CI (-191.72,-89.03),P＜ 0.001],BUN[MD =-5.49,95 ％ CI (-8.36,-2.63),P＜ 0.001] and 24 h-Upro [MD =-0.43,95 ％ CI (-0.62,-0.23),P＜ 0.001],with statistical significance.CONCLUSIONS:The clinical efficacy of Haikun shenxi capsule in the treatment of CRF is good and significantly improve related indexes of renal function.
RESUMEN
OBJECTIVE:To systematically review therapeutic efficacy of Haikun shenxi capsule in the treatment of chronic renal failure (CRF).METHODS:Retrieved from Central,PubMed,EMBase,CJFD,CBM,VIP and Wanfang database,randomized clinical trials (RCTs) about Haikun shenxi capsule combined with routine treatment (trial group)vs.single routine treatment (control group) in the treatment of CRF were collected.Meta-analysis was performed by Rev Man 5.3 software after screening literature,extracting data and evaluating quality by using risk bias evaluation of Cochrane collaboration network.RESULTS:A total of 10 RCTs were included eventually,involving 704 patients.The results of analysis showed that compared to general therapy,Haikun shenxi capsule could improve total effective rate [RR =4.42,95 ％ CI (2.70,7.22),P＜ 0.001],and could reduce SCr[MD =-140.37,95 ％ CI (-191.72,-89.03),P＜ 0.001],BUN[MD =-5.49,95 ％ CI (-8.36,-2.63),P＜ 0.001] and 24 h-Upro [MD =-0.43,95 ％ CI (-0.62,-0.23),P＜ 0.001],with statistical significance.CONCLUSIONS:The clinical efficacy of Haikun shenxi capsule in the treatment of CRF is good and significantly improve related indexes of renal function.
RESUMEN
Objective To study the effect of Haikun Shenxi Capsule(HSC)on endothelin-1(ET-1)and mRNA expression of rats with adriamyein-induced nephrosis and proliferation of glomerular mesangial cells(GMCs)cultured in vitro.Methods The rats were randomized into 6 groups,normal group,sham operation group,model group,benazepril group,HSC low-and high-dose groups.Ten weeks after treatment,ET-1 and mRNA expression were measured with immunohistochemical and hybridization in situ method.Tak- ing the Benazepril group as the control group,the proliferation of GMCs was detected with MTT method.Results In the model group,ET-1 and mRNA expression presented a strong positive,compared with which,that of the HSC low-and high-dose groups was remarkably reduced(P
RESUMEN
AIM:To investigate the effect of Haikun Shenxi Capsule(fucoidan)on disorder of lipid metabolism on the patients with chronic kidney disease(CKD).METHODS:98 patients with CKD 3、4 stage were divided into 2 groups at random:control group were given routine therapy and therapy group were given routine therapy plus Haikun Shenxi Capsule.The changes of the levels of TCH,TG,HDL-Ch,LDL-Ch,VLDL-Ch,ApoA-1,ApoB in 2 groups were observed.RESULTS:The level of TCH,TG decreased significantly(P 0.05).CONCLUSION:Haikun Shenxi Capsule has a positive effect on disorder of lipid metabolism on the patients with CKD.
RESUMEN
AIM: To investigate the effect of Haikun Shenxi Capsule(Fucoidan) on tubule function in chronic kidney disease(CKD) patients. METHODS: One hundred and one patients with CKD 2、3 stage were randomly divided into two groups dom: control group were given routine therapy and therapy group were given routine therapy plus Haikunshenxi Capsule.We observed the changes of the level of UOP、NAG、?_1-MG in two groups. RESULTS: The level of NAG、?_1-MG significantly decreased,urine osmoticpressure significatly increased(P0.05). CONCLUSION: Haikun Shenxi Capsule has a protective effect on tubule in CKD patients.